analyzed to understand the molecular basis of GC, ( 6, 7) but only a few with frequent alterations have been identified so far.
Previously, we identified the human homolog of Drosophila prune protein (PRUNE, which encodes h-prune) as a glycogen synthase kinase 3 (GSK-3)-binding protein. ( 8) GSK-3 inhibitors or small interfering RNA (siRNA) for GSK-3 and h-prune inhibit cell motility. H-prune is localized to focal adhesions, and the siRNA for GSK-3 or h-prune delays the disassembly of paxillin. Tyrosine phosphorylation of focal adhesion kinase (FAK) and activation of Rac are suppressed in GSK-3 or h-prune knock-down cells. ( 8) These results suggest that GSK-3 and h-prune act cooperatively to regulate cellular motility. In fact, overexpression of h-prune has been reported in breast cancers and is also associated with high metastatic potential. ( 9) In our previous study, overexpression of h-prune was correlated with T grade (depth of invasion), N grade (degree of lymph node metastasis), and tumor stage in colorectal cancers (CRC). ( 8) H-prune has phosphodiesterase (PDE) activity, with a preferential affinity for cAMP over cGMP as substrate. ( 9) PDE are a diverse superfamily of molecules that catalyze the hydrolysis of 3',5'-cyclic nucleotides to their corresponding nucleoside 5'-monophosphates.
( 10) H-prune PDE activity is involved in cellular motility, ( 9) and h-prune also interacts with nm23-H1 (NME1, which encodes nm23-H1), ( 11) a known suppressor of cancer metastasis. ( 12) H-prune and nm23-H1 proteins partially colocalize in the cytoplasm. ( 11) It has been suggested that overexpression of h-prune inhibits the antimetastasis function of nm23-H1 during the metastatic process. ( 9, 13) Several studies have suggested an association between reduced expression of nm23 mRNA or protein and increasing metastatic activity, resulting in poorer prognosis in breast cancers, ( 14) malignant melanomas ( 15) and hepatocellular carcinomas. ( 16) In contrast, in GC and CRC, overexpression of nm23-H1 has been reported. ( 17, 18) High nm23-H1 expression has been shown to correlate with tumor progression and poor prognosis of GC. ( 19) Taken together, the currently available data suggest that analysis of h-prune is necessary to clarify the association between expression of nm23-H1 and metastatic potential.
Correlation between high nm23-H1 expression and metastatic potential in GC may be due to overexpression of h-prune. However, expression of h-prune has not been investigated in GC. In the present study, we examined the expression and distribution of both h-prune and nm23-H1 in human GC by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR).
Tissue samples. In a retrospective study design, 181 primary tumors were collected from patients diagnosed with GC who underwent surgery between 1991 and 2001 at the Department of Surgical Oncology, Hiroshima University Hospital (Hiroshima, Japan).
All patients underwent curative resection. Only patients without preoperative radiotherapy or chemotherapy and without clinical evidence for distant metastasis were enrolled in the study.
For quantitative RT-PCR, 38 GC samples and corresponding non-neoplastic mucosa samples were used. The samples were obtained during surgery at Hiroshima University
Hospital. We confirmed microscopically that the tumor specimens were predominantly cancer tissue (>50% on a nuclear basis). Samples were frozen immediately in liquid nitrogen and stored at -80°C until use.
For immunohistochemical analysis, we used archival formalin-fixed, paraffin-embedded tissues from 143 patients who had undergone surgical excision for GC. Fifty-nine of the 143 patients had early GC, and 84 had advanced GC. Early GC is limited to the mucosa or the mucosa and submucosa, regardless of nodal status. ( 2) Advanced GC is a tumor that has invaded beyond the muscularis propria. Information on patient prognosis was available for 84 GC cases. Because information on postoperative chemotherapy was not available, postoperative chemotherapeutic backgrounds were not involved in the prognostic analysis.
Tumor staging was carried out according to the tumor-node-metastasis (TNM) stage grouping. ( 20) Quantitation of PRUNE mRNA levels in human tissue samples was done by real-time fluorescence detection as described previously. ( 22) PRUNE primer sequences were 5'-GAA GTC CTG GAA CGC TCC C-3' and 5'-GGT TAG GGT GGG TAC TTG AGG C-3'. PCR was carried out using a SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City, CA, USA). Real-time detection of the emission intensity of SYBR green bound to double-stranded DNA was done with an ABI PRISM 7700
Sequence Detection System (Applied Biosystems) as described previously. ( 23) ACTB-specific PCR products were amplified from the same RNA samples and served as internal controls.
Immunohistochemistry. A Dako LSAB kit (Dako, Carpenteria, CA, USA) was used for immunohistochemical analysis. In brief, sections were pretreated by microwaving in citrate buffer for 30 min to retrieve antigenicity. After peroxidase activity was blocked with 3% H 2 O 2 -methanol for 10 min, sections were incubated with normal goat serum (Dako) for 20 min to block non-specific antibody binding sites. Sections were incubated with rabbit polyclonal antih-prune (diluted 1:50, antih-prune antibody was raised in our laboratory) ( 8) and rabbit polyclonal antinm23-H1 (1:20, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The specificity of the h-prune antibody has been characterized in detail. Immunohistochemical analysis of h-prune in GC . We next investigated the expression and distribution of h-prune by immunohistochemistry of 143 GC tissue samples. In corresponding non-neoplastic gastric mucosa, only weak or no staining of h-prune was observed in epithelial and stromal cells (Fig. 2a,b) . However, GC tissue showed stronger, more extensive staining than corresponding non-neoplastic mucosa. In 14 (10%) of the 143 GC cases, h-prune-positive tumor cells were restricted to the invasive front (Fig. 2a,c,d ). In these cases, less than 50% of tumor cells were stained.
However, in the majority of GC cases containing h-prune-positive tumor cells, more than 50% of the tumor cells showed cytoplasmic staining for h-prune (43 of 143 GC cases). In these GC cases, h-prune-positive tumor cells were observed at the invasive front in addition to the central part of the tumors. The remaining cases showed 10-50%
immunopositive tumor cells and h-prune staining was not observed at the invasive front.
H-prune was detected in the cytoplasm of tumor cells in intestinal-type ( Fig. 2e ) and diffuse-type GC (Fig. 2f,g ). We next analyzed the relationship between h-prune expression and clinicopathological characteristics. Several previous studies have indicated that observation of the invasive front is important in the analysis of tumor cells, because it reflects the invasive potential of those cells. To investigate the significance of restricted h-prune staining at the invasive front, the relationship between h-prune staining and clinicopathological characteristics was examined in GC cases in which less than 50% of tumor cells were stained. In these cases, GC cases in which h-prune-positive tumor cells were restricted to the invasive front showed more advanced T grade (P = 0.0083, Fisher's exact test) than those in which h-prune-positive tumor cells were not restricted to the invasive front (Table 1) . GC cases in which h-prune-positive tumor cells were restricted to the invasive front did not show advanced N grade or tumor stage (Table 1 ). In contrast, among all of the cases we studied, GC cases in which more than 50% of tumor cells were stained showed more advanced T grade (P = 0.0158, Fisher's exact test), N grade (P = 0.0035, Fisher's exact test) and tumor stage (P = 0.0466, Fisher's exact test) than those in which less than 50% of tumor cells were stained (Table 1) . Therefore, when more than 50% of tumor cells were stained, the immunostaining was considered positive for h-prune.
Association between h-prune and nm23-H1 expression. Because it has been suggested that overexpression of h-prune in breast cancer inhibits the antimetastasis function of nm23-H1 during metastasis, ( 9, 13) we also carried out immunohistochemical analysis of nm23-H1 in the same 143 GC cases. Consistent with previous reports, ( 19) strong cytoplasmic staining of nm23-H1 was observed in tumor cells. In corresponding non-neoplastic mucosa, weak staining of nm23-H1 was observed. In the present study,
to compare the h-prune staining pattern with the nm23-H1 staining pattern, the same cut-off point for nm23-H1 and h-prune immunostaining was set. When more than 50% of tumor cells were stained, the immunostaining was considered positive for nm23-H1.
In total, 124 (87%) of 143 GC cases were positive for nm23-H1. The h-prune staining pattern was then compared with the nm23-H1 staining pattern. Of 43 h-prune-positive GC cases, 42 (98%) were positive for nm23-H1, and in these 42 GC cases there was a tendency for h-prune and nm23-H1 to be expressed in the same tumor cells (Fig. 3a,b ).
All 18 GC cases that were negative for both h-prune and nm23-H1 were signet ring cell carcinoma. In contrast, the majority (82 of 143 GC cases, 57%) of cases were positive for nm23-H1 but not h-prune (Fig. 3c,d ). The frequency of nm23-H1 expression in h-prune-positive GC cases (42 of 43 cases, 98%) was significantly higher than that in h-prune-negative GC cases (82 of 100 cases, 82%, P = 0.0134, Fisher's exact test) ( Table 2) .
We next analyzed the relationship between nm23-H1 expression and clinicopathological characteristics. Expression of nm23-H1 was not correlated with age, sex, T grade, N grade or tumor stage ( Table 3) . As reported previously, ( 19) expression of nm23-H1 was observed more frequently in intestinal-type GC (79 of 85 cases, 93%) than in diffuse-type GC (45 of 58 cases, 78%, P = 0.0113, Fisher's exact test) ( Table 3) . It has been reported that in the majority of nm23-H1-positive tumors, more than 75% of the tumor cells contained a homogeneous cytoplasmic pattern for nm23-H1. ( 19) Fig. 4a-c) . In contrast, among h-prune-negative GC cases there was no statistically significant correlation between nm23-H1 positivity and T grade, N grade or tumor stage ( Fig. 4a-c) .
We also examined the relationship between survival and expression of h-prune and nm23-H1 in GC (n = 84). On univariate analysis, T grade (P < 0.0001, log-rank test), N grade (P = 0.0474, log-rank test), tumor stage (P = 0.0001, log-rank test) and h-prune expression (P < 0.0001, log-rank test) ( (Table 4) .
Discussion
Metastasis fundamentally involves the movement of cells from one site to another. The molecular mechanisms that underlie cell migration involve dynamic cytoskeletal changes, cell-matrix interactions, localized proteolysis, actin-myosin contractions and focal contact disassembly. ( 25) We reported previously that h-prune is localized to focal adhesions and that knockdown of h-prune inhibits cell motility. Suppression of tyrosine phosphorylation of FAK and activation of Rac are involved in inhibition of cell motility. ( 8) In the present study, overexpression of PRUNE mRNA was observed in promising biomarker predicting nodal metastasis of colorectal cancers. ( 26) Overexpression of heparanase at the invasive front has been reported in GC, and high expression of heparanase is a strong predictor of poor survival. ( 27) These results indicate that the proteolytic degradation of extracellular matrix by these molecules is one of the most important mechanisms in tumor progression, and the proteolytic degradation occurs at the invasive front. Because h-prune promotes cell motility, expression of h-prune at the invasive front may partly contribute to the malignant behavior of GC, such as local invasiveness.
The mechanism of regulation of h-prune expression is still unknown. In the present study, overexpression of PRUNE mRNA was observed in 32% by quantitative RT-PCR analysis, and h-prune-positive GC cases were found in 30% by immunohistochemistry.
Because GC samples analyzed by quantitative RT-PCR were different from those analyzed by immunohistochemistry, we could not compare PRUNE mRNA levels with h-prune protein levels. However, these findings suggest that overexpression of PRUNE occurs at the transcriptional or mRNA level in GC. PRUNE amplification and overexpression have been reported in certain sarcomas and breast cancers. ( 13) PRUNE is located on chromosome 1q21.3, and gains of 1q21.1-21.2 and 1q21.3 have been reported in GC. ( 28) Amplification of the PRUNE gene may be involved in overexpression of h-prune in GC cases. The main cause of peptic ulceration is Helicobacter pylori, and H. pylori is the strongest risk factor for the development of distal GC. ( 29, 30) Because stimulation of matrilysin by H. pylori has been reported, ( 31) induction of h-prune by H. pylori should be examined in the near future.
In the present study, immunohistochemical analysis of GC tissues revealed that almost all h-prune-positive GC cases (98%) also expressed nm23-H1. Expression of nm23-H1
was found in both early-and late-stage GC, whereas expression of h-prune was detected which is involved in cellular motility, is enhanced by the interaction with nm23-H1, ( 9) expression of both proteins may confer cellular motility to GC cells. Among h-prune-negative GC cases, there were no clear differences between nm23-H1 positivity and clinical characteristics, suggesting that expression of only nm23-H1 does not influence progression of GC. Although there was no impact of nm23-H1 expression on patient survival in the present study, it has been reported that high nm23-H1 expression correlates with tumor progression and poor prognosis. ( 9) Expression of nm23-H1 may enhance the PDE activity of h-prune but may not have antimetastatic activity. All 18
GC cases negative for both h-prune and nm23-H1 were signet ring cell carcinoma.
Several reports have indicated that the prognosis of patients with signet ring cell carcinoma is relatively favorable in the early stages and poor in advanced stages compared with other histological types of GC. ( 32) In fact, of 18 signet ring cell carcinoma cases, 12 cases showed stage I and the prognosis of patients with these GC was favorable.
Epigenetic changes, such as DNA methylation of CpG islands, are detected commonly in human cancers. Hypermethylation of CpG islands is associated with silencing of many genes, especially defective tumor-related genes, and has been proposed as an alternative way to inactivate tumor-related genes in human cancers. ( 33) GC show the CpG island methylator phenotype (CIMP). ( 34, 35) CIMP-positive GC also tend to show DNA methylation of the p16 INK4a , ( 34) hMLH1 ( 6) and RIZ ( 6) genes, suggesting that CIMP is an important pathway involved in stomach carcinogenesis. Because DNA methylation inhibitors such as 5-aza-2'-deoxycytidine have been shown to increase nm23-H1 expression in breast cancer cells, ( 36) h-prune or nm23-H1 expression may be associated with CIMP.
Is h-prune a good therapeutic target for GC? Previous data indicated that dipyridamole, an antiplatelet aggregation drug, inhibits h-prune PDE activity and cellular motility in a breast cancer cell line. ( 9) In the SW480 CRC cell line, knockdown of h-prune decreased cell motility. ( 8) These results suggest that inhibition of h-prune may be useful for the prevention or treatment of metastasis. However, because h-prune is expressed ubiquitously in normal human adult tissues, ( 11) inhibitors of h-prune, such as dipyridamole, may have severe adverse effects. However, it is known that components of the blood-clotting pathway contribute to metastasis by trapping tumor cells in capillaries or by facilitating adhesion of tumor cells to capillary walls. Anti-platelet aggregation drugs may interfere with this step in the metastatic process. In fact, several studies have indicated that the formation of metastatic tumors could be inhibited by antiplatelet aggregation drugs (reviewed by Hejna et al. (37) ). In GC, combined chemotherapy with dipyridamole with adriamycin and 5-fluorouracil appears to be safe and may be useful clinically for treatment of GC. ( 38) Taken together with our present results, h-prune inhibitors, such as dipyridamole, may be effective for the prevention or treatment of h-prune-positive GC without severe adverse effects. The PDE superfamily is large and complex, containing 11 highly related and structurally related gene families and over 60 distinct isoforms. Each of the PDE families contains one to four genes, and many genes generate multiple isoforms. ( 39) Development of specific h-prune inhibitors is important because dipyridamole also inhibits the activities of PDE5, PDE6, PDE7, PDE8, PDE10 and PDE11. ( 39) In conclusion, we found that h-prune is overexpressed in GC and that this overexpression correlates with tumor progression and poor survival in patients with GC.
Although the significance of overexpression of nm23-H1 is still unclear, nm23-H1 may contribute to tumor cell motility by upregulating the function of h-prune. Although the precise mechanism by which h-prune regulates cellular motility remains unclear, the efficacy of a combination chemotherapy with 5-fluorouracil, cisplatin and dipyridamole ( 40) should be investigated in h-prune-positive GC. 
